This study identified serum microRNA (miRNA) combinations for detecting diffuse glioma and for discriminating among glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and metastatic brain tumor.
Why this matters
To improve clinical outcomes, a blood-based screening tool for detecting diffuse glioma is necessary. The results from this study suggest that evaluation of serum miRNAs is suitable for primary screening of brain tumors. The development of blood-based diagnostic tools for the detection of brain tumors may improve patient outcomes.